{
    "clinical_study": {
        "@rank": "107607", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "Study to assess the safety and tolerability of ascending single-doses of REGN1193 in healthy\n      volunteers."
        }, 
        "brief_title": "An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy men and women 18 to 45 years of age (inclusive)\n\n          2. Body mass index 18.0 to 30.0 kg/m^2 (inclusive)\n\n          3. Normal standard 12-lead ECG\n\n          4. Willing and able to comply with clinic visits and study-related procedures\n\n          5. Provide signed informed consent\n\n          6. For sexually active men and women of childbearing potential, willingness to utilize\n             adequate contraception and not become pregnant (or have their partner[s] become\n             pregnant) during and for up to 3 months after participation in the study.\n\n        Exclusion Criteria:\n\n          1. Any clinically significant abnormalities or other characteristics that would preclude\n             the  subject from safely enrolling or successfully completing the study\n\n          2. History of drug or alcohol abuse within a year prior to the screening visit\n\n          3. Current regular smoking, or a history of smoking greater than \u00bd pack\n\n          4. Receipt of an investigational drug within 30 days of screening, or within 5\n             half-lives of  the investigational drug or therapy being studied (whichever is\n             longer)\n\n          5. Significant concomitant illness or history of significant illness such as cardiac,\n             renal,  neurological, endocrinological, metabolic or lymphatic disease, or any other\n             illness or  condition that may adversely affect the subject's participation in this\n             study\n\n          6. Known history of human immunodeficiency virus (HIV) antibody; and/or positive\n             hepatitis B surface antigen (HBsAg), and/or positive hepatitis C antibody (HCV) at\n             the screening visit\n\n          7. Hospitalization for any reason within 60 days of screening\n\n          8. History or presence of malignancy (including carcinoma in situ) prior to the\n             screening  visit\n\n          9. Any subject who is the investigator or any sub-investigator, research assistant,\n             pharmacist, study coordinator, or other staff directly involved in the conduct of the\n              protocol, or family member of staff involved in the conduct of the protocol\n\n         10. Pregnant or breast-feeding women\n\n        (The inclusion/ exclusion criteria provided above are not intended to contain all\n        considerations relevant to a subject's potential participation in this clinical trial)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933763", 
            "org_study_id": "R1193-HV-1219"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "intervention_name": "REGN1193", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Adminstrator Clinical Trials"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in this study is the incidence and severity of TEAEs (treatment emergent adverse events) in healthy volunteers treated with REGN1193 or placebo reported from day 1 (baseline) to the completion of the study on day 106/ visit 16.", 
            "measure": "Number of TEAEs", 
            "safety_issue": "Yes", 
            "time_frame": "day 1 to day 106"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933763"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Serum concentrations of REGN1193 over time", 
            "measure": "Serum concentration", 
            "safety_issue": "No", 
            "time_frame": "day 1 to day 106"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}